Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children

World Journal of Pediatrics

Volumn 13, Issue 4, 2017, Pages 321-327

  Shan, Li Shen ^a   Liu, Xin ^a   Kang, Xin Yuan ^a   Wang, Fei ^a   Han, Xiao Hua ^a   Shang, Yun Xiao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

immunoglobulin; methylprednisolone; refractory Mycoplasma pneumoniae pneumonia

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; D DIMER; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE;

ARTICLE; ATELECTASIS; CHILD; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; OPEN STUDY; PATIENT COMPLIANCE; PLEURA EFFUSION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY MYCOPLASMA PNEUMONIAE PNEUMONIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANTIBIOTIC RESISTANCE; CHINA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION STUDY; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MYCOPLASMA PNEUMONIAE; PRESCHOOL CHILD; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANALYSIS OF VARIANCE; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85010799942     PISSN: 17088569     EISSN: 18670687     Source Type: Journal    
DOI: 10.1007/s12519-017-0014-9     Document Type: Article

References (35)

1. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr 2010;10:48.
2. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57:223–228.
3. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2014;49:377–380.
4. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22–26.
5. Shen Y, Zhang J, Hu Y, Shen K. Combination therapy with immune-modulators and moxifloxacin on fulminant macrolideresistant Mycoplasma pneumoniae infection: a case report. Pediatr Pulmonol 2013;48:519–522.
6. Attilakos A, Palaiologou P, Lagona E, Voutsioti A, Dinopoulos A. Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin. Pediatr Neurol 2008;38:357–359.
7. Bressan S, Mion T, Andreola B, Bisogno G, Da Dalt L. Severe Mycoplasma pneumoniae-associated mucositis treated with immunoglobulins. Acta Paediatr 2011;100:e238–e240.
8. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:617–630.
9. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158–2159.
10. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010;67:355–358.
11. Xu YC, Zhu LJ, Xu D, Tao XF, Li SX, Tang LF, et al. Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou. World J Pediatr 2011;7:240–244.
12. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642–1649.
13. Wang JY, Lee CH, Cheng SL, Chang HT, Hsu YL, Wang HC, et al. Comparison of the clinical manifestations of severe acute respiratory syndrome and Mycoplasma pneumoniae pneumonia. J Formos Med Assoc 2004;103:894–899.
14. Seo YH, Kim JS, Seo SC, Seo WH, Yoo Y, Song DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr 2014;57:186–192.
15. Tanir G, Aydemir C, Yilmaz D, Tuygun N. Internal carotid artery occlusion associated with Mycoplasma pneumoniae infection in a child. Turk J Pediatr 2006;48:166–171.
16. Fu M, Wong KS, Lam WW, Wong GW. Middle cerebral artery occlusion after recent Mycoplasma pneumoniae infection. J Neurol Sci 1998;157:113–115.
17. Snowden N, Wilson PB, Longson M, Pumphrey RS. Antiphospholipid antibodies and Mycoplasma pneumoniae infection. Postgrad Med J 1990;66:356–362.
18. Guo SC, Xu CW, Liu YQ, Wang JF, Zheng ZW. Changes in plasma levels of thrombomodulin and D-dimer in children with different types of Mycoplasma pneumoniae pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:619–622. [In Chinese]
19. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78–86.
20. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32:956–973.
21. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263–268.
22. Weiss AK, Hall M, Lee GE, Kronman MP, Sheffler-Collins S, Shah SS. Adjunct corticosteroids in children hospitalized with community-acquired pneumonia. Pediatrics 2011;127:e255–e263.
23. Lin WC, Lee PI, Lu CY, Hsieh YC, Lai HP, Lee CY, et al. Mycoplasma pneumoniae encephalitis in childhood. J Microbiol Immunol Infect 2002;35:173–178.
24. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42–47.
25. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509–521.
26. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev 2004;15:157–168.
27. Lu A, Wang L, Zhang X, Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid. Pediatr Pulmonol 2011;46:1093–1097.
28. Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology 2011;133:51–61.
29. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;198:1180–1188.
30. Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J 2008;32:259–264.
31. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697–728, table of contents.
32. Ahluwalia J, Wan J, Lee DH, Treat J, Yan AC. Mycoplasmaassociated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. Pediatr Dermatol 2014;31:664–669.
33. Mofenson LM, Shearer WT, Moye J, Nugent R, Willoughby A. Manipulating the immune system with immune globulin. The National Institute of Child Health and Human Development. Intravenous Immunoglobulin Study Group. N Engl J Med 1992;326:1636–1637; author reply 1637-1638.
34. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002;12:133–139.
35. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci 2007;1110:497–506.